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GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing
cellular hyper-O-GlcNAcylation
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O-GlcNAcylation is an essential, dynamic and inducible post-
translational glycosylation of cytosolic proteins in metazoa and
can show interplay with protein phosphorylation. Inhibition of
OGA (O-GlcNAcase), the enzyme that removes O-GlcNAc from
O-GlcNAcylated proteins, is a useful strategy to probe the role
of this modiﬁcation in a range of cellular processes. In the
present study, we report the rational design and evaluation of
GlcNAcstatins, a family of potent, competitive and selective
inhibitors of human OGA. Kinetic experiments with recombinant
humanOGArevealthattheGlcNAcstatinsarethemostpotenthu-
man OGA inhibitors reported to date, inhibiting the enzyme
in the sub-nanomolar to nanomolar range. Modiﬁcation of the
GlcNAcstatin N-acetyl group leads to up to 160-fold selectivity
against the human lysosomal hexosaminidases which employ
a similar substrate-assisted catalytic mechanism. Mutagenesis
studies in a bacterial OGA, guided by the structure of a
GlcNAcstatincomplex,providesinsightintotheroleofconserved
residues in the human OGA active site. GlcNAcstatins are
cell-permeant and, at low nanomolar concentrations, effectively
modulate intracellular O-GlcNAc levels through inhibition of
OGA, in a range of human cell lines. Thus these compounds
are potent selective tools to study the cell biology of O-GlcNAc.
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INTRODUCTION
Reversible post-translational modiﬁcation of many cytoplasmic
and nuclear proteins in eukaryotic cells by glycosylation of
serine and threonine residues with β-linked N-acetylglucosamine
(O-GlcNAc) has been shown to play important roles in cellular
processes as diverse as DNA transcription and translation,
insulin sensitivity, protein trafﬁcking and degradation [1–4].
Dysregulation of O-GlcNAc appears to play a role in human
pathogenesis, such as cancer [5–7] and Alzheimer’s disease [8–
12]. O-GlcNAc is also implicated in Type 2 diabetes [13,14];
however, the precise mechanism is still controversial [15].
In higher eukaryotes only two enzymes are responsible for the
dynamic cycling of O-GlcNAc, the OGT (O-GlcNAc transferase;
CAZY family GT41 [16]) which transfers GlcNAc on to proteins
from the UDP-GlcNAc donor, and the OGA (O-GlcNAcase;
CAZY family GH84 [17]), which catalyses the removal of
O-GlcNAc. The precise molecular mechanisms by which OGT
and OGA recognize and act on hundreds of proteins remain to be
discovered [18].
Inhibition of hOGA (human OGA) with PUGNAc [O-(2-acet-
amido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarb-
amate] (Figure 1A) (Ki =50 nM [19,20]) has been used exten-
sively to study the role of O-GlcNAc in a range of cellular
processes [21–27]. Crystal structures of bacterial hOGA homolo-
gues have become available [28,29], and it has been shown that
PUGNAc is a tight-binding inhibitor, with its imidolactone ring
mimicking the half-chair/envelope conformation of the pyranose
ring in the transition state by virtue of the stable oxime moiety
[28,30]. However, PUGNAc also potently inhibits the human
HexA/B (hexosaminidases A/B; CAZY family GH20), genetic
inactivation of which has been associated with the Tay–Sachs and
Sandhofflysosomalstoragedisorders[31].Structuralanalysishas
revealed that the acetamido group of PUGNAc resides in a deep
pocket that is signiﬁcantly larger in OGAs than in the lysosomal
HexA/HexB [28,29,32]. The feasibility of constructing more
selective PUGNAc analogues, as well as other hOGA inhibitors
that exploit the difference in the size of the N-acyl binding
pocket, has previously been explored [20,33,34]. Increasing the
size of the N-acyl substituents, however, also resulted in weaker
(micromolar) inhibition of hOGA. Furthermore, PUGNAc
is acid-labile [35]. Thiazoline, another inhibitor of GH20/84
enzymes [32,36,37], has also been similarly chemically modiﬁed
to achieve more selective OGA inhibition, yielding derivatives
that inhibited in the low micromolar range with three orders of
magnitude selectivity towards hOGA [20,33], culminating in
the recent report of the thiazoline derivative thiamet-G, with
selectivity towards hOGA, inhibiting it with a Ki of 21 nM [38].
We have recently reported a novel scaffold, GlcNAcstatin, a
potent inhibitor of a bacterial OGA orthologue, exploiting the
structural similarity of Z-PUGNAc and the naturally occurring
potent Hex inhibitor nagstatin (Figure 1A) [39–41]. Inhibition
of β-glycosidases with nagstatin-related sugar-imidazoles has
been examined by Heightman and Vasella [42], who suggested
that lateral protonation of the exo-cyclic nitrogen atom of
the imidazole ring should account for the excellent inhibiting
properties of these compounds. Indeed, GlcNAcstatin inhibited a
bacterial OGA orthologue in the picomolar range, and structural
analysisrevealedatightinteractionbetweenthecatalyticacidand
the (presumably protonated) imidazole [41].
In the present study, we report that GlcNAcstatin also potently
inhibits hOGA, with a Ki in the low nanomolar range. We also
show that this compound is able to induce hyper-O-GlcNAcy-
lation in a range of human cell lines when used at low nanomolar
Abbreviations used: GST, glutathione transferase; HEK, human embryonic kidney; Hex, hexosaminidase; 4MU-NAG, 4-methylumbelliferyl-N-acetyl-β-D-
glucosaminide; OGA, O-GlcNAcase; CpOGA, Clostridium perfringens OGA; hOGA, human OGA; OGT, O-GlcNAc transferase; PUGNAc, O-(2-acetamido-
2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate.
The structural co-ordinates reported will appear in the Protein Data Bank under accession code PDB 2WB5.
1 To whom correspondence should be addressed (email dava@davapc1.bioch.dundee.ac.uk).
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Figure 1 Kinetic characterization of GlcNAcstatin derivatives
(A) Chemical structures of the glycosidase inhibitors PUGNAc, nagstatin and the GlcNAcstatin scaffold. (B) Lineweaver–Burk analysis of hOGA steady-state kinetics measured in the presence of
0–40nMGlcNAcstatinC.DatawereﬁttedusingthestandardequationforcompetitiveinhibitionintheGraFitprogram(ErithacusSoftware).(C)Dose–responsecurveofGlcNAcstatinsA–Eincubated
with lysosomal HexA/HexB. Data were ﬁtted using the standard IC50 equation in the GraphFit program (Erithacus Software).
concentrations. Furthermore, we report four new GlcNAcstatin
derivatives that explore potency and selectivity of this scaffold,
with one of these being the most potent hOGA inhibitor reported
sofar,inhibitingwithaKi of420pM.Guidedbyacrystalstructure
of one of these derivatives in complex with a bacterial OGA,
we probe key interactions through mutagenesis. These novel
molecules will be useful tools for the study of OGA in a range of
cellular signal transduction pathways.
MATERIALS AND METHODS
Cloning, protein expression and puriﬁcation
The previously described plasmid for expression of the OGA
orthologue from CpOGA (Clostridium perfringens OGA) [28]
was used as a template to carry out mutagenesis of Val
331 to
cysteine, using the QuikChange® kit (Stratagene) with the
following primers: 5
 -GGGAGATGTAAAACCATTAATAACA-
TGCCCAACAGAGTATGATACTGGAGC-3
  and 5
 -GCTCCA-
GTATCATACTCTGTTGGGCATGTTATTAATGGTTTTACAT-
CTCCC-3
 . W490A mutagenesis was performed using the same
protocol and techniques with primers: 5
 -GGACAATAAAACT-
GCGGCTAAATCAGGAAG-3
  and 5
 -CTTCCTGATTTAGC-
CGCAGTT TTATTGTCC-3
 .The constructs were veriﬁed by
DNA-sequencing. V331C-CpOGA, W490A-CpOGA and wild-
type protein were expressed and puriﬁed following the protocol
described previously [28,41,43].
hOGA (amino acid residues 53–916) was cloned into a
modiﬁed version of pGEX6P-1, lacking the BamHI site, and
the hOGA sequence was inserted using EcoRI and NotI sites,
after an internal EcoRI site was removed by introducing a silent
mutation. The protein was expressed in Escherichia coli BL21
(DE3) cells overnight at 15◦C using 10 μM IPTG (isopropyl
β-D-thiogalactoside; D600 of 0.4–0.6). The cells were harvested
by centrifugation (3500 g for 30 min at 4◦C) and lysed with
sonication in lysis buffer [50 mM Tris/HCl (pH 7.5), 250 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% 2-mercaptoethanol,
0.2 mM PMSF and 1 mM benzamidine]. The recombinant GST
(glutathionetransferase)-fusionproteinwasboundtoglutathione–
Sepharose beads that were pre-equilibrated in washing buffer
[50 mM Tris/HCl (pH 7.5), 250 mM NaCl, 1 mM EGTA, 0.1%
2-mercaptoethanol, 0.2 mM PMSF and 1 mM benzamidine]. The
fusion protein was eluted using the washing buffer supplemented
with20 mMglutathioneandthepHwasadjustedto7.5.Theeluted
protein was dialysed into 50 mM Tris/HCl (pH 7.5), 0.1 mM
EGTA,150 mMNaCl,0.07%2-mercaptoethanol,0.1 mMPMSF
and 1 mM benzamidine.
Determination of the CpOGA–GlcNAcstatin D complex structure
CpOGA was crystallized as described previously [28,41,43]. An
aliquot of 1 μl of a suspension of GlcNAcstatin D in mother
liquor was added to the crystallized protein in a 2.25 μld r o p
(1 μl of protein plus 1 μl of mother liquor plus 0.25 μlo f
40%γ-butyrolactone).After50 minat20◦C(roomtemperature)
the crystal was cryoprotected by 5 s immersion in 0.17 M
ammonium sulfate, 0.085 M sodium cacodylate (pH 6.5), 25.5%
PEG [poly(ethylene glycol)] 8000 and 15% glycerol, and
frozen in a nitrogen cryostream. Data were collected at the
European Synchrotron Radiation Facility on beamline ID14-1
to 2.3 Å (1 Å=0.1 nm), with an overall Rmerge of 0.074 and
98.2% completeness. Reﬁnement was initiated from the native
CpOGA–GlcNAcstatin C complex (PDB entry 2J62, [41]). Well-
deﬁned Fo−Fc electron density for the inhibitor was observed
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Figure 2 Structural analysis of GlcNAcstatin derivatives and PUGNAc in complex with CpOGA
(A)StereoviewofGlcNAcstatinD(stickswithgreencarbon,redoxygenandbluenitrogenatoms)intheactivesiteofCpOGA(stickswithgreycarbon).Hydrogenbondsareindicatedbyblackbroken
lines.Unbiased|Fo|–|Fc|,ϕcalc electrondensitymap(2.75σ)isshownasacyanchickenwire.(B)StereoviewofsuperimposedcrystallographicallydeterminedcomplexesofCpOGAwithGlcNAcstatin
C (PDB number 2J62) (colour scheme as in A) and PUGNAc (PDB number 2CBJ) (sticks with light blue carbon), black broken lines showing hydrogen bonds for the CpOGA–GlcNAcstatin complex.
(Figure 2A), allowing placement of an inhibitor model, built with
the help of a PRODRG [44] structure and topology. Iterative
model building using COOT [45] and reﬁnement with REFMAC
[46] yielded the ﬁnal model with good statistics (R, Rfree:18.5,
23.8).
Inhibition measurements
Steady-state kinetics of wild-type hOGA and CpOGA
mutants were determined using the ﬂuorogenic substrate
4MU-NAG (4-methylumbelliferyl-N-acetyl-β-D-glucosaminide;
Sigma). Standard reaction mixtures (50 μl) contained 2 pM
CpOGAmutantin50 mMcitricacid,125 mMNa2HPO4 (pH 5.5),
0.1 mg/ml BSA, and 1.5–25 μM of substrate in water. Steady-
state kinetics of GlcNAcstatin C were performed in the presence
of different concentrations of the inhibitor (0, 35, 70 and 140
pM). The reaction mixtures were incubated at 20◦C for 466 min.
For hOGA, the 50 μl standard reaction volume contained 2 nM
hOGA–GST(53–916),McIlvainebuffer-system(0.2 MNa2HPO4
mixedwith0.1 Mcitricacid,pH 5.7),0.1 mg/mlBSA,0–250 μM
4MU-NAG with various GlcNAcstatin C concentrations (0, 10,
20 and 40 nM). The reaction was run for 60 min.
All reactions were stopped (before more than 10% of the
substrate was consumed) by the addition of 100 μlo f3 M
glycine/NaOH (pH 10.3). The ﬂuorescence of the released 4-
methylumbelliferone was quantiﬁed using a FLX 800 Microplate
Table 1 Inhibition data of GlcNAcstatins A–E and PUGNAc against
lysosomal HexA/HexB, hOGA and the compounds selectivity for hOGA
Values are means+ −S.D. n.s., no selectivity for hOGA.
Compound Hex A/B, Ki (nM)* hOGA, Ki (nM) Selectivity (GH20/hOGA)
GlcNAcstatin A 0.55+ −0.05 4.3+ −0.2 n.s.
GlcNAcstatin B 0.17+ −0.05 0.42+ −0.06 n.s.
GlcNAcstatin C 550+ −10 4.4+ −0.1 164
GlcNAcstatin D 2.7+ −0.4 0.74+ −0.09 4
GlcNAcstatin E 1100+ −100 8500+ −300 n.s.
PUGNAc 25+ −2.5 35+ −6* n.s.
*The Cheng–Prusoff equation {Ki=IC50/1+([S]/Km)} was used to convert the IC50 values
into an absolute inhibition constant (Ki).
Fluorescence Reader (Bio-Tek), with excitation and emission
wavelengths of 360 and 460 nm respectively. The mode of
inhibition was visually veriﬁed by the Lineweaver–Burk plot
(Figure 1B), and the Ki was determined by ﬁtting all ﬂuorescence
intensitydatatothestandardequationforcompetitiveinhibitionin
GraFit (Erithacus Software) (Tables 1 and 2). IC50 measurements
with a mixture of human Hex A/B activities (purchased from
Sigma, catalogue number A6152) against GlcNAcstatin A–E
and PUGNAc were performed using the ﬂuorogenic 4MU-NAG
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Table 2 Michaelis–Menten parameters of CpOGA wild-type and mutants
and Ki values against GlcNAcstatin C
Values are means+ −S.D.
Enzyme Ki (nM) Km (μM) kcat (s−1)
Wild-type 4.6+ −0.1 2.9+ −0.2 10.5+ −0.2
V331C 98.1+ −6.4 6.8+ −0.4 17.3+ −0.7
W490A 74.0+ −5.6 100+ −10 65+ −3
substrate and standard reaction mixtures as described previously
[41,43], with the following changes: 5 μ-units/ml enzyme
mixture was used with a ﬁxed substrate concentration at the Km
(230 μM)inthepresenceofdifferentconcentrationsoftheinhibi-
tors, 100 pM to 100 μM (GlcNAcstatins) and 10 pM to 1 mM
(PUGNAc).
Cell-based assays and Western blot analysis
Cell lines were maintained in DMEM [Dulbecco’s modiﬁed
Eagle’s medium; containing 1 g/l glucose for HEK (human
embryonic kidney)-293 cells, and 4.5 g/l glucose for HeLa, HT-
1080, SH-SY5Y and U-2 OS cells] supplemented with 10%
(v/v) foetal bovine serum. Subconﬂuent cells were treated with
various concentrations of inhibitors in the presence of 0.1%
DMSO. After 6 h, cells were washed once in ice-cold PBS and
harvested in the following lysis buffer: 50 mM Tris (pH 7.4),
0.27 M sucrose, 1 mM sodium orthovanadate, 1 mM EDTA,
1 mM EGTA, 10 mM sodium β-glycerophosphate, 50 mM NaF,
1%TritonX-100,0.1%2-mercaptoethanol,1 mMbenzamidine,
0.1 mM PMSF and 5 μM leupeptin. Cell debris was removed
by centrifugation (13000 g for 10 min at 4◦C), and supernatants
were analysed byimmunoblotting. For Westernblot analysis, 15–
30 μg of total cellular protein was separated by SDS/PAGE, and
O-GlcNAcylation was detected with the anti-O-GlcNAc antibody
CTD110.6. An anti-β-tubulin antiserum was used as a loading
control. The O-GlcNAc signal in each lane was quantiﬁed using
the AIDA (Advanaced Image Data Analyzer) software version
3.27, and normalized against the β-tubulin signal.
RESULTS AND DISCUSSION
GlcNAcstatins: a new family of potent hOGA inhibitors
Exploiting the available structural data of a complex of a C.
perfringens OGA orthologue (CpOGA, [28,41]), GlcNAcstatins
A–E were designed and synthesized (Figure 1A, details of
synthesis to be reported elsewhere; for further details please
contact the corresponding author). GlcNAcstatins A–E fall into
two subfamilies, based on their modiﬁcation on the C-2 position
of the imidazole ring. GlcNAcstatin A carries the carboxymethyl
group, whereas GlcNAcstatins B–E carry a phenylethyl moiety.
GlcNAcstatin C carries an isobutyl group instead of the smaller
N-acetyl group in GlcNAcstatin A and B, GlcNAcstatin D an
N-propionyl group, and GlcNAcstatin E an N-imidazole group.
The increased length of the N-acyl derivative was explored to
determinethemostusefulsubstituenttospeciﬁcallyinhibithOGA
over the lysosomal Hexs.
GlcNAcstatins are (sub)nanomolar inhibitors of hOGA
ApreviousreportonGlcNAcstatinCshowedpicomolarinhibiton
of an apparent hOGA orthologue from the bacterium C. perfrin-
gens (CpOGA) [41], whereas inhibition of hOGA remained to
be explored. GlcNAcstatins A–E were tested in dose–response
experiments against recombinant hOGA, with subsequent
Lineweaver–Burk analysis revealing competitive inhibition
againsttheenzymes(Table1andFigure1B).GlcNAcstatinsA–D
inhibit the human enzyme in the low nanomolar to subnanomolar
range (Table 1 and Figure 1B). GlcNAcstatins B and D are the
most potent hOGA inhibitors with Ki values of 0.4 and 0.7 nM
respectively, being, to the best of our knowledge, the most potent
hOGA inhibitors currently available. GlcNAcstatins A and C are
equally potent with Ki values of 4.3 nM and 4.4 nM respectively.
GlcNAcstatin E inhibits only in the micromolar range.
Tuning of hOGA/Hex selectivity
All GlcNAcstatin derivatives were evaluated against human
lysosomal Hexs to investigate their potential selectivity towards
hOGA (Table 1 and Figure 1C). GlcNAcstatin A is the smallest
GlcNAcstatin family member. It carries the N-acetyl moiety
and the carboxymethyl group, and inhibits hOGA in the nano-
molar range. Assaying lysosomal HexA/B shows that the
compound equally potently inhibits the GH20 enzymes (Ki of
550 pM) (Table 1). The ﬁrst modiﬁcation we addressed was to
substitute the carboxymethyl group to obtain GlcNAcstatin B,
similar to previous work showing that a β-glycosidase from C.
saccharolyticum is more potently inhibited with a phenylethyl-
substituted glucoimidazole [47]. Indeed, GlcNAcstatin B is
approx. 10-fold more potent against hOGA (Ki of 420 pM)
than GlcNAcstatin A. However, it also inhibits HexA/B more
potently, giving a Ki of 170 pM (Table 1). The IC50 data show that
GlcNAcstatin B is (to the best of our knowledge) also the most
potent HexA/B inhibitor currently known, with a Ki of 170 pM,
followed by GlcNAcstatin A (Ki of 550 pM). With these suitably
potent inhibitors in hand we attempted to address selectivity by
modifying the N-acetyl group. The addition of a single methyl
group to obtain an N-propionyl sidechain (GlcNAcstatin D)
already leads to different inhibition proﬁles between hOGA and
humanlysosomalHexA/HexB (Table1),witha15-foldreduction
in inhibition of HexA/B. Further extension to an isobutyl group
(GlcNAcstatinC)reducesHexA/Binhibitionmorethan200-fold,
giving selectivities of 164-fold for hOGA, whereas incorporation
of a larger imidazole group resulted in loss of both potency and
selectivity (Table 1 and Figure 1C).
Probing key GlcNAcstatin binding residues
To further understand the structural basis for selectivity, we
determined the crystal structure of CpOGA in complex with
GlcNAcstatin D (Figure 2). These data show that GlcNAcstatin D
binds deep into the active site of CpOGA, with the sugar moiety
adoptinga
4Econformation,andassumingthesameconformation
as observed for the GlcNAcstatin C complex [41]. Interestingly,
the structural data point towards two active site residues that may
play a key role in the surprisingly large difference in activity
and selectivity of the GlcNAcstatins towards the hOGA/CpOGA
and HexA/B. The only non-conserved residue near the N-acetyl
binding pocket in CpOGA is Val
331, corresponding to Cys
215
in hOGA. Unbiased |Fo|−|Fc| density of the GlcNAcstatin D
complex deﬁnes that the N-propionyl group points towards this
non-conserved Val
331 and occupies a single deﬁned conformation,
interacting with the Cβ/γ carbons (Figure 2A). Furthermore,
the phenyl moiety from GlcNAcstatin D is seen to interact
with a solvent-exposed tryptophan residue (Trp
490), similar to
the phenyl moiety from PUGNAc and GlcNAcstatin C in the
respective CpOGA complexes [28,41] (Figure 2B). From a
sequence alignment between CpOGA and hOGA, it is not clear
whether an equivalently positioned aromatic residue exists in the
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation 225
humanenzyme[28].Therelativecontributionstobindingofthese
residues were probed by mutagenesis in CpOGA. Mutation of
Val
331 to cysteine resulted in a mutant enzyme with unaltered
steady-state kinetics compared with wild-type CpOGA (Table 2).
However,Lineweaver–BurkanalysisusingGlcNAcstatinCasthe
inhibitor,givesa25-foldreducedKi of98pM(Table2)compared
withthewild-typeenzyme.Thusalthoughthecysteine,conserved
in metazoan OGAs, is not involved in catalysis, it does contribute
to deﬁning the shape of the N-acetyl pocket.
Mutation of Trp
490 to alanine resulted in a mutant enzyme that
showed a 30-fold reduction in Km when assayed with the pseudo-
substrate 4MU-NAG (Table 2). Inhibition by GlcNAcstatin C
is similarly affected, with the Ki for W490A-CpOGA being
almost 20-fold reduced (Ki =74 pM compared with Ki =4p M
for the wild-type enzyme; Table 2). In comparison, PUGNAc
exhibitsa3-foldreducedbindingafﬁnityagainstW490A-CpOGA
[28]. However, structural comparisons show that the PUGNAc
phenylcarbamate moiety occupies a different position in the
active site of CpOGA (Figure 2B) and lacks the stacking
interactions with Trp
490 that are observed in the GlcNAcstatin
complexes.IntheabsenceofanhOGAcrystalstructure,itremains
unknown whether an equivalent of Trp
490 (His
433 in Bacillus
thetaiotaomicron OGA, [29]) exists in the human enzyme.
GlcNAcstatins effectively induce cellular hyper-O-GlcNAcylation at
low nanomolar concentrations
The intended application of the GlcNAcstatins is to inhibit
hOGA in live human cells, resulting in hyper-O-GlcNAcylation
by disrupting the balance between O-GlcNAc transfer and
hydrolysis. Suchmodulation ofO-GlcNAc levelswould allowfor
the study of O-GlcNAc-dependent signal transduction processes.
To evaluate the use of the GlcNAcstatins for cell biological
studies, HEK-293 cells were exposed to various concentrations
of GlcNAcstatins for 6 h, followed by investigation of O-
GlcNAc levels on cellular proteins by Western blot analysis
using an anti-O-GlcNAc antibody (CTD110.6) (Figure 3A).
GlcNAcstatins B–D increase cellular O-GlcNAc levels of
numerous intracellular proteins when used at concentrations as
low as 20 nM. GlcNAcstatins A and E appear to be less potent
as quantitatively assessed from the Western blots, requiring
micromolar concentrations in the cell-based assay for a marked
effect inside the cells. For GlcNAcstatin E, this is in agreement
withtheinvitroinhibitiondatathatshowthatthiscompoundisthe
weakest hOGA inhibitor (Table 1). The reduced cellular activity
of GlcNAcstatin A could be due to differences in membrane
permeabilityresultingfromthelesshydrophobicnatureoftheC-2
carboxymethyl substituent. Taken together, these results suggest
that GlcNAcstatins are cell-permeant compounds that modulate
O-GlcNAcylation levels within the cells by inhibiting hOGA.
We also have investigated the potency of the most selective
GlcNAcstatin (GlcNAcstatin C) against a range of different
cell lines (Figure 3B). HeLa (adenocarcinoma), HT-1080
(ﬁbrosarcoma), SH-SY5Y (neuroblastoma) and U-2 OS
(osteosarcoma) cells were treated for 6 h with 20 nM and 5 μM
inhibitor concentrations. In comparison with the untreated cells,
whole-cell lysate analysis with the anti-O-GlcNAc-antibody
showed a concentration-dependent hyper-O-GlcNAcylation in
all four cell lines, with an increase already detectable at a 20 nM
concentration of the compound (Figure 3B).
Concluding remarks
We have explored a new family of potent and competitive OGA
inhibitors, the GlcNAcstatins, based on the GlcNAc–imidazole
Figure 3 Immunoblot detection of O-GlcNAc modiﬁcations on cellular
proteins using an anti-O-GlcNAc antibody
TheincreaseinO-GlcNAclevelsincomparisonwithuntreatedsamplesisshowninthehistogram
underneath the blot. (A) HEK-293 cells were treated with GlcNAcstatins A–E for 6h with the
concentrations indicated. (B) GlcNAcstatin C was added to HeLa, HT-1080, SH-SY5Y or U-2
OS cells for 6h with the identical inhibitor concentrations as in (A). The molecular mass in kDa
is indicated on the left-hand side of each blot.
scaffold. Based on structural analysis with GlcNAcstatin C [41]
and GlcNAcstatin D in complex with CpOGA we can explain the
potency of this inhibitor family. All GlcNAcstatins interact with
theactivesiteofOGAsformingatleasteightconservedhydrogen
bonds(Figures2Aand2B),thepyranoseringadoptsafavoured
4E
conformation, and conserved interactions with Asp
297 and Asn
396
force the N2 substituent to adopt a conformation compatible with
the proposed substrate-assisted catalytic mechanism [20,28,29],
with the carbonyl oxygen approaching the sp
2 hybridized carbon
to within 3.4 Å.
GlcNAcstatins A–D inhibit hOGA in the low-nanomolar to
sub-nanomolar range, while CpOGA is inhibited in the low
picomolarrange,implyingthattherearesome(minor)differences
in the GlcNAc-binding pocket between hOGA and CpOGA, even
though the active sites of these enzymes are almost identical as
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assessed by sequence alignment [28]. We have identiﬁed two
key active-site residues, Val
331/Trp
490, which are responsible for
stronger interactions of GlcNAcstatins with CpOGA compared
with hOGA. It still remains unknown to what extent the GlcNAc-
statin aglycon can be modiﬁed in order to increase the binding
afﬁnity for the human active site, given the possible structural
divergence between the human/bacterial enzymes in this area.
GlcNAcstatins are to the best of our knowledge the most
potent competitive inhibitors of hOGA. They can be used
in cell-based assays in nanomolar concentrations to increase
cellular O-GlcNAc levels in vivo in a range of human cell
lines. Thus GlcNAcstatins provide a valuable tool for functional
investigations of this post-translational modiﬁcation and its
involvement in signalling pathways within the eukaryotic cell.
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